CTT PHARMACEUTICAL HOLDINGS, INC.: 10-Q filed 2014-07-28
What CTT PHARMACEUTICAL HOLDINGS, INC. reported in its quarterly report filed 2014-07-28 (fiscal Q2 2014): 18 published measures, 64 facts as tagged in accession 0001062993-14-004384.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2014-07-28
- Fiscal period
- fiscal Q2 2014
- Accession
- 0001062993-14-004384 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All CTT PHARMACEUTICAL HOLDINGS, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-06-30 | 227,543 | USD | |
| At 2013-12-31 | 6,252 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-06-30 | 141,987 | USD | |
| At 2013-12-31 | 249,378 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-06-30 | 85,556 | USD | |
| At 2013-12-31 | -243,126 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-06-30 | 222,114 | USD | |
| At 2014-03-31 | 11,790 | USD | |
| At 2013-12-31 | 823 | USD | |
| At 2013-06-30 | 7,916 | USD | |
| At 2013-03-31 | 19,000 | USD | |
| At 2012-12-31 | 12,091 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-04-01 to 2014-06-30 | -44,298 | USD | 91 |
| 2014-01-01 to 2014-06-30 | -73,333 | USD | 181 |
| 2013-04-01 to 2013-06-30 | -63,709 | USD | 91 |
| 2013-01-01 to 2013-06-30 | -104,158 | USD | 181 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-04-01 to 2014-06-30 | -28,737 | USD | 91 |
| 2014-01-01 to 2014-06-30 | -46,282 | USD | 181 |
| 2013-04-01 to 2013-06-30 | -33,871 | USD | 91 |
| 2013-01-01 to 2013-06-30 | -107,540 | USD | 181 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-04-01 to 2014-06-30 | 386,750 | USD | 91 |
| 2014-01-01 to 2014-06-30 | 386,750 | USD | 181 |
| 2013-04-01 to 2013-06-30 | 0 | USD | 91 |
| 2013-01-01 to 2013-06-30 | 0 | USD | 181 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-04-01 to 2014-06-30 | -147,689 | USD | 91 |
| 2014-01-01 to 2014-06-30 | -119,177 | USD | 181 |
| 2013-04-01 to 2013-06-30 | 22,787 | USD | 91 |
| 2013-01-01 to 2013-06-30 | 103,365 | USD | 181 |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-04-01 to 2014-06-30 | 22,346,611 | shares | 91 |
| 2014-01-01 to 2014-06-30 | 15,915,826 | shares | 181 |
| 2013-04-01 to 2013-06-30 | 9,413,581 | shares | 91 |
| 2013-01-01 to 2013-06-30 | 9,413,581 | shares | 181 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-04-01 to 2014-06-30 | 22,346,611 | shares | 91 |
| 2014-01-01 to 2014-06-30 | 15,915,826 | shares | 181 |
| 2013-04-01 to 2013-06-30 | 9,413,581 | shares | 91 |
| 2013-01-01 to 2013-06-30 | 9,413,581 | shares | 181 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-04-01 to 2014-06-30 | 0 | USD/shares | 91 |
| 2014-01-01 to 2014-06-30 | 0 | USD/shares | 181 |
| 2013-04-01 to 2013-06-30 | -0.01 | USD/shares | 91 |
| 2013-01-01 to 2013-06-30 | -0.01 | USD/shares | 181 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-04-01 to 2014-06-30 | 0 | USD/shares | 91 |
| 2014-01-01 to 2014-06-30 | 0 | USD/shares | 181 |
| 2013-04-01 to 2013-06-30 | -0.01 | USD/shares | 91 |
| 2013-01-01 to 2013-06-30 | -0.01 | USD/shares | 181 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-04-01 to 2014-06-30 | -22,322 | USD | 91 |
| 2014-01-01 to 2014-06-30 | -49,525 | USD | 181 |
| 2013-04-01 to 2013-06-30 | -62,535 | USD | 91 |
| 2013-01-01 to 2013-06-30 | -122,854 | USD | 181 |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-04-01 to 2014-06-30 | 22,322 | USD | 91 |
| 2014-01-01 to 2014-06-30 | 49,525 | USD | 181 |
| 2013-04-01 to 2013-06-30 | 62,535 | USD | 91 |
| 2013-01-01 to 2013-06-30 | 122,854 | USD | 181 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-06-30 | 35,184,737 | shares | |
| At 2013-12-31 | 35,184,737 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-06-30 | 12,944,924 | USD | |
| At 2013-12-31 | 12,663,857 | USD |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-04-01 to 2014-06-30 | -44,298 | USD | 91 |
| 2014-01-01 to 2014-06-30 | -73,333 | USD | 181 |
| 2013-04-01 to 2013-06-30 | -63,709 | USD | 91 |
| 2013-01-01 to 2013-06-30 | -109,142 | USD | 181 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-04-01 to 2014-06-30 | 12,112 | USD | 91 |
| 2014-01-01 to 2014-06-30 | 25,077 | USD | 181 |
| 2013-04-01 to 2013-06-30 | 28,109 | USD | 91 |
| 2013-01-01 to 2013-06-30 | 64,282 | USD | 181 |
Inspect the source
- Entity
- CTT PHARMACEUTICAL HOLDINGS, INC. / CIK 0001035422
- Captured
- SEC response SHA-256
21b0a0ba4c84772224f4978cbe9507956b8d731d5fe56b447e41295eab5239b0
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001035422.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))